X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.

Recent Posts

New report shows 200 medicines in development for heart disease and stroke

By Andrew Powaleny  |    February 20, 2018
Cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in the United States, accounting for one out of every three deaths. According to the American Heart...   Read More

ICYMI: Why 2017 medicine approvals matter

By Andrew Powaleny  |    January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...   Read More

ICYMI –Report highlights increasing prevalence for Alzheimer’s disease

By Andrew Powaleny  |    December 11, 2017
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild...   Read More

World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation

By Andrew Powaleny  |    December 1, 2017
Today marks World AIDS Day, a moment to reflect on the significant advances made in the treatment and prevention of HIV, the virus which causes AIDS. The incredible scientific progress...   Read More

Supporting opportunities for enhanced competition in the marketplace

By Andrew Powaleny  |    November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...   Read More

Honoring veterans serving in the biopharmaceutical industry

By Andrew Powaleny  |    November 11, 2017
In honor of Veterans Day, we spoke with Rob Caskey, a senior manager in PhRMA’s finance department about his military service, journey to PhRMA and why veterans make great employees for America’s...   Read More

New report and event examine the new era of vaccines

By Andrew Powaleny  |    November 9, 2017
Today, leading minds will come together for an in-depth conversation centered on vaccines – their critical role in warding off disease, the innovative science powering breakthroughs in their...   Read More

A new era in cancer

By Andrew Powaleny  |    November 1, 2017
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds...   Read More

PhRMA, member companies and NIH create public-private partnership for immuno-oncology

By Andrew Powaleny  |    October 12, 2017
The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took a significant...   Read More

More than 85 medicines in development for Alzheimer’s disease

By Andrew Powaleny  |    September 21, 2017
When Brian Kursonis started “blanking out” for moments at a time, a scan revealed plaques of a protein called amyloid in the brain, one sign of Alzheimer’s disease. A test of his spinal fluid...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates